Besim Ogretmen to Recurrence
This is a "connection" page, showing publications Besim Ogretmen has written about Recurrence.
Connection Strength
0.163
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.079
-
Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation. Front Immunol. 2022; 13:904823.
Score: 0.042
-
Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022 07; 36(7):1907-1915.
Score: 0.042